Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bio-Three Hi Tablet
- Development stage
- Phase 4
- Lead developer
- Toa Pharmaceuticals
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bio-Three Hi Tablet is an over-the-counter (OTC) probiotic combination product developed by Alinamin Pharmaceutical and originated by Toa Pharmaceutical. It is formulated as a designated quasi-drug in Japan to regulate the intestinal environment and alleviate symptoms such as constipation, loose stools, diarrhea, and abdominal bloating. The tablet contains a symbiotic combination of three active bacterial strains: butyric acid bacteria (*Clostridium butyricum* TO-A), lactic acid bacteria (*Enterococcus faecium* T-110), and saccharifying bacteria (*Bacillus subtilis* TO-A). These three strains function symbiotically across different regions of the gastrointestinal tract—from the small intestine to the large intestine—to promote the growth of beneficial bacteria, produce essential metabolites like butyrate and lactic acid, and support the barrier function of the large intestine.
- Brand names
- Bio-Three Hi Tabletビオスリー
- Other names
- Bacillus subtilis + Clostridium butyricum + Enterococcus faeciumBacillus subtilis TO-A + Clostridium butyricum TO-A + Enterococcus faecium T-110Viosley
Beyond the preview
Go deeper on Bio-Three Hi Tablet.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bio-Three Hi Tablet.